Semaglutide shortage declared over, starting the clock on compounded copies
With the shortage resolved, pharmacies that had been making copies of semaglutide got a fixed window to wind down. Tirzepatide had gone through the same step weeks earlier.
What's new
FDA removed semaglutide from its shortage list and set end dates for compounding: about 60 days for state-licensed pharmacies, about 90 for outsourcing facilities.
Why it matters
Millions of people had switched to cheaper compounded versions during the shortage. Their supply route was about to close.
What's next
Watch for enforcement letters, legal challenges from compounders and new cash-price offers from manufacturers.
The US Food and Drug Administration said the shortage of semaglutide injection products had been resolved, ending the legal basis that let pharmacies make large volumes of copies.
Why copies were allowed at all
US law lets pharmacies compound a drug that is "essentially a copy" of an approved product only in limited cases, one of which is when the product is on the official shortage list. Demand for GLP-1 medicines outran supply from 2022 onward, and a large compounding market grew around that exception.
The wind-down
- State-licensed compounding pharmacies (section 503A) received roughly 60 days.
- Outsourcing facilities (section 503B) received roughly 90 days.
- After those dates, making copies of the approved product is generally no longer permitted.
Why the agency was cautious about copies
FDA had already logged reports of dosing errors with compounded semaglutide, often linked to multi-dose vials and units confusion. Some products sold online used salt forms, such as semaglutide sodium, that are not the substance in approved medicines.
What it means for patients
People using compounded versions were told to talk to their prescriber about switching. Manufacturers, meanwhile, expanded direct-to-patient programmes with lower cash prices for some doses, partly to win back that market.
